Selective delivery of radionuclides to tumors may be accomplished using a two-step
approach, in which in the first step the tumor is pretargeted with an unlabeled antibody …

Labeled antibodies, as well as their fragments and antibody-derived recombinant constructs,
have long been proposed as general vectors to target radionuclides to tumor lesions for …

Bispecific antibodies are artificially generated antibodies, engineered to present two
different binding sites per molecule. Thus, simultaneous targeting of different epitopes on the …

Pretargeted radioimmunotherapy (PRIT) with the β-emitting radionuclide 177Lu is an
attractive approach to treat carcinoembryonic antigen (CEA)–expressing tumors. The …

Colorectal cancer is a worldwide health burden, with high incidence and mortality,
especially in the advanced stages of the disease. Preclinical models are very important and …

Peritoneal carcinomatosis (PC) is considered incurable, and more effective therapies are
needed. Herein we test the hypothesis that GPA33-directed intracompartmental pretargeted …

Purpose Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies (bsMAb) and a
radiolabeled peptide reduces the radiation dose to normal tissues. Here we report the …

Introduction Peritoneal carcinomatosis (PC) is an advanced malignancy that is not sensitive
to systemic conventional chemotherapy. Treatment options for PC are usually palliative …

We describe a mouse model of rectal cancer (RC) involving rapid tumor organoid
engraftment via orthotopic transplantation in an immunocompetent setting. This approach …

Personalized medicine is becoming an integral part of our healthcare system, in which
theranostics play a fundamental role. Nanomedicines such as monoclonal antibodies are a …